Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-08-30
2005-08-30
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100
Reexamination Certificate
active
06936698
ABSTRACT:
Antibodies having reduced immunogenicity and methods for making them are disclosed.
REFERENCES:
patent: 5225539 (1993-07-01), Winter
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5639641 (1997-06-01), Pedersen et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5756096 (1998-05-01), Newman et al.
patent: 5800988 (1998-09-01), Casterman et al.
patent: 5856135 (1999-01-01), Tsuchiya et al.
patent: WO 91/09967 (1991-07-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/17105 (1993-09-01), None
patent: WO 96/16990 (1996-06-01), None
Co et al (PNAS 88:2869-2873, 1991).
Colnot et al (Cancer Immunol Immunother. 52:576-82, 2003 abstract.
Cobleigh et al (J of Clinical Oncology 17:2639-2648, 1999.
Panka et al., PNAS 85:3080-3084, 1988.
Amit et al., Science 233:747, 1986.
Rudikoff et al., PNAS 79:1979-1983, 1982.
Vijh-Warrier et al., Molecular Immunology 32:1081-1092, 1995.
Greenspan, NS, Bona, CA.Idiotypes:structures and immunogenicity. FASEB J.(1993) Mar.;7(5):436-44. Abstract.
Kuus-Reichel, et al.Will Immunogenicity Limit the Use, Efficacy, and Future Development of Therapeutic Monoclonal Antibodies? Clinical and Diagnostic Laboratory Immunology.Jul. 1994, 1(4):365-372.
S. Tonegawa, “Somatic Generation of Antibody Diversity”,Nature, vol. 302, pp. 575-581 (1983).
Vigh-Warrier, et al. “Characterization of the Variable Regions of a Chimpanzee Monoclonal Antibody with Potent Neutralizing Activity Against HIV-1”,Molecular Immunology, vol. 32, pp. 1081-1092 (1995).
Anderson et al. “A Primatized Mab to Human CD4 Causes Receptor Modulation, without Marked Reduction in CD4+T Cells in Chimpazees: In Vitro and in Vivo Characterization of a Mab (IDEC-CE9.1) to Human CD4”,Clinical Immunology and Immunopathology, vol. 84, No. 1, pp. 73-84 (1997).
Kettleborough, et al., “Humanization of a Mouse Monoclonal Antibody by CDR-Grafting: the Importance of Framework Residues on Loop Conformation,”Protein Engineering, 4(7):773-783 (1991).
Riechmann, et al., “Reshaping Human Antibodies for Therapy,”Nature, 332(6162):323-327 (Mar. 24, 1998).
Queen, et al., “A Humanized Antibody that Bind to the Interleukin 2 Receptor,”Proceedings of the National Academy of Sciences of USA, 86(24):10029-10033 (Dec. 1, 1989).
Mary M. Bending, “Humanization of Rodent Monoclonal Antibodies by CDR Grafting,”Methods: A Companion to Methods in Enzymology, 8:83-93 (1995).
Lewis, et al., “Cloning and Sequence Analysis of κ and γ Cynomolgus Monkey Immunoglobulin cDNA's,”Developmental and Comparative Immunology, 17(6):549-560 (1993).
Gimmi Edward R.
Hecht Elizabeth J.
Helms Larry R.
Lockenour Andrea V.
SmithKline Beecham
LandOfFree
Monoclonal antibodies with reduced immunogenicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies with reduced immunogenicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies with reduced immunogenicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3521212